To compare the effect of pioglitazone vs vildagliptin in type 2 diabetes mellitus patients not responding to combination of metformin and sulfonylureas.
Not Applicable
Completed
- Conditions
- Health Condition 1: null- Type 2 Diabetes Mellitus patients uncontrolled with metformin and sulfonylureas
- Registration Number
- CTRI/2013/04/003582
- Lead Sponsor
- investigator initiated trial
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
Type 2 DM, taking a combination of metformin + sulfonylurea (glibenclamide or glipizide or gliclazide or glimepride) for at least last 3 months with HbA1c >7% <=11%, BMI >25 kg/m2, FBS >126 mg/dl
Exclusion Criteria
Pregnant and lactating females, patients on insulin therapy, history of type 1 DM, evidence of diabetic complications (nephropathy, neuropathy and retinopathy), patients with clinical signs and symptoms of acute myocardial infarction, liver failure, chronic heart failure and renal failure
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HbA1c levelsTimepoint: 0 week and 12 weeks
- Secondary Outcome Measures
Name Time Method Fasting plasma glucose levels (mg/dl)Timepoint: Baseline (0 week) and at week 12